Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 3/2018

01-03-2018 | Original Article

The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases

Authors: Yun Wang, Hao-cheng Lin, Ma-yan Huang, Qiong Shao, Zhi-qiang Wang, Feng-hua Wang, Yun-fei Yuan, Bin-kui Li, De-shen Wang, Pei-rong Ding, Gong Chen, Xiao-jun Wu, Zhen-hai Lu, Li-ren Li, Zhi-zhong Pan, Peng Sun, Shu-mei Yan, De-sen Wan, Rui-hua Xu, Yu-hong Li

Published in: Cancer Immunology, Immunotherapy | Issue 3/2018

Login to get access

Abstract

Background

The Immunoscore was initially established to evaluate the prognosis of stage I/II/III colorectal cancer patients. However, the feasibility of the Immunoscore for the prognosis of colorectal cancer liver metastases (CRCLM) has not been reported.

Methods

Liver metastases in 249 CRCLM patients were retrospectively analyzed. The Immunoscore was assessed according to the counts and densities of CD3+ and CD8+ T cells in the central- and peritumoral areas by immunohistochemistry. The prognostic role of the Immunoscore for relapse–free survival (RFS) and overall survival (OS) was analyzed with Kaplan–Meier curves and Cox multivariate models, and confirmed via an internal validation. Receiver operating characteristic (ROC) curves were plotted to compare the prognostic values of the Immunoscore and the clinical risk score (CRS) system.

Results

CRCLM patients with high Immunoscores (> 2) had significantly longer RFS [median RFS (95% confidence interval; 95% CI) 21.4 (7.8–35.1) vs. 8.7 (6.8–10.5) months, P < 0.001] and OS [median OS (95% CI): not reached vs. 28.7 (23.2–34.2) months, P < 0.001] than those with low Immunoscores (≤ 2). After stratification by CRS, the Immunoscore retained a statistically significant prognostic value for OS. The areas under the ROC curves (AUROCs) of the Immunoscore and the CRS system for RFS were 0.711 [95% CI 0.642–0.781] and 0.675[95% CI 0.601–0.749] (P = 0.492), whereas the AUROC of the Immunoscore system for OS was larger than that of the CRS system [0.759 (95% CI 0.699–0.818) vs. 0.660 (95% CI 0.592–0.727); P = 0.029].

Conclusions

The Immunoscore of liver metastases can be applied to predict the prognosis of CRCLM patients following liver resection.
Appendix
Available only for authorised users
Literature
1.
Mayo SC, Pawlik TM (2009) Current management of colorectal hepatic metastasis. Expert Rev Gastroenterol Hepatol 3:131–144CrossRefPubMed
2.
Shah A, Alberts S, Adam R (2008) Accomplishments in 2007 in the management of curable metastatic colorectal cancer. Gastrointest Cancer Res 2:S13–S18PubMedPubMedCentral
3.
Leporrier J, Maurel J, Chiche L et al (2006) A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg 93:465–474CrossRefPubMed
4.
Ito K, Govindarajan A, Ito H et al (2010) Surgical treatment of hepatic colorectal metastasis: evolving role in the setting of improving systemic therapies and ablative treatments in the 21st century. Cancer J 16:103–110CrossRefPubMed
5.
Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRefPubMed
6.
D’Angelica M, Kornprat P, Gonen M et al (2011) Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Ann Surg Oncol 18:1096–1103CrossRefPubMed
7.
Abdalla EK, Vauthey JN, Ellis LM et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825 (discussion 825–827) CrossRefPubMedPubMedCentral
8.
Biasco G, Derenzini E, Grazi G et al (2006) Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. Cancer Treat Rev 32:214–228CrossRefPubMed
9.
Parks R, Gonen M, Kemeny N et al (2007) Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 204:753–761 (discussion 761–763) CrossRefPubMed
10.
Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318 (discussion 318–321) CrossRefPubMedPubMedCentral
11.
Halama N, Michel S, Kloor M et al (2011) Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 71:5670–5677CrossRefPubMed
12.
Katz SC, Bamboat ZM, Maker AV et al (2013) Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol 20:946–955CrossRefPubMed
13.
Nakagawa K, Tanaka K, Homma Y et al (2015) Low infiltration of peritumoral regulatory T cells predicts worse outcome following resection of colorectal liver metastases. Ann Surg Oncol 22:180–186CrossRefPubMed
14.
Maker AV, Ito H, Mo Q et al (2015) Genetic evidence that intratumoral T-cell proliferation and activation are associated with recurrence and survival in patients with resected colorectal liver metastases. Cancer Immunol Res 3:380–388CrossRefPubMedPubMedCentral
15.
Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964CrossRefPubMed
16.
Galon J, Fridman WH, Pages F (2007) The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 67:1883–1886CrossRefPubMed
17.
Galon J, Mlecnik B, Bindea G et al (2014) Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 232:199–209CrossRefPubMed
18.
19.
20.
Van Cutsem E, Cervantes A, Nordlinger B et al (2014) Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):i1–i9CrossRef
21.
Galon J, Fox BA, Bifulco CB et al (2016) Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J Transl Med 14:273CrossRefPubMedPubMedCentral
22.
Pages F, Kirilovsky A, Mlecnik B et al (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27:5944–5951CrossRefPubMed
23.
Pages F, Berger A, Camus M et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654–2666CrossRefPubMed
24.
Gabrielson A, Wu Y, Wang H et al (2016) Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res 4:419–430CrossRefPubMedPubMedCentral
25.
Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964CrossRefPubMed
26.
Ward-Hartstonge KA, McCall JL, McCulloch TR et al (2017) Inclusion of BLIMP-1+ effector regulatory T cells improves the Immunoscore in a cohort of New Zealand colorectal cancer patients: a pilot study. Cancer Immunol Immunother 66:515–522CrossRefPubMed
27.
Katz SC, Pillarisetty V, Bamboat ZM et al (2009) T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol 16:2524–2530CrossRefPubMed
28.
Brunner SM, Kesselring R, Rubner C et al (2014) Prognosis according to histochemical analysis of liver metastases removed at liver resection. Br J Surg 101:1681–1691CrossRefPubMed
29.
Brudvik KW, Henjum K, Aandahl EM et al (2012) Regulatory T-cell-mediated inhibition of antitumor immune responses is associated with clinical outcome in patients with liver metastasis from colorectal cancer. Cancer Immunol Immunother 61:1045–1053CrossRefPubMed
30.
Nakagawa K, Tanaka K, Homma Y et al (2015) Low infiltration of peritumoral regulatory T cells predicts worse outcome following resection of colorectal liver metastases. Ann Surg Oncol 22:180–186CrossRefPubMed
31.
Nakagawa K, Tanaka K, Homma Y et al (2015) Low infiltration of peritumoral regulatory T cells predicts worse outcome following resection of colorectal liver metastases. Ann Surg Oncol 22:180–186CrossRefPubMed
32.
Halama N, Michel S, Kloor M et al (2011) Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 71:5670–5677CrossRefPubMed
33.
Mlecnik B, Bindea G, Kirilovsky A et al (2016) The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med 8:326r–327rCrossRef
34.
Shinto E, Hase K, Hashiguchi Y et al (2014) CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer. Ann Surg Oncol 21(3):S414–S421CrossRefPubMed
Metadata
Title
The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases
Authors
Yun Wang
Hao-cheng Lin
Ma-yan Huang
Qiong Shao
Zhi-qiang Wang
Feng-hua Wang
Yun-fei Yuan
Bin-kui Li
De-shen Wang
Pei-rong Ding
Gong Chen
Xiao-jun Wu
Zhen-hai Lu
Li-ren Li
Zhi-zhong Pan
Peng Sun
Shu-mei Yan
De-sen Wan
Rui-hua Xu
Yu-hong Li
Publication date
01-03-2018
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 3/2018
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-017-2094-8

Other articles of this Issue 3/2018

Cancer Immunology, Immunotherapy 3/2018 Go to the issue

Original Article

High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients

Original Article

Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737

Original Article

Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells

Original Article

Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors

Review

Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC

Original Article

Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits